Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07467564) titled 'The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis' on March 9.

Study Type: Observational

Primary Sponsor: Sanofi

Condition: Atopic Dermatitis

Intervention: Drug: Dupilumab

Recruitment Status: Recruiting

Date of First Enrollment: February 24, 2026

Target Sample Size: 184

Countries of Recruitment: United Arab Emirates

To know more, visit https://clinicaltrials.gov/study/NCT07467564

Disclaimer: Curated by HT Syndication....